Surgery, Gastroenterology and Oncology
Vol. 23, No. 2, Apr 2018
The Combination of Serum Cystatin C, Urinary Kidney Injury Molecule-1 and MELD plus Score Predicts Early Acute Kidney Injury after Liver Transplantation
Marian-Irinel Tudoroiu, Georgiana Constantin, Liliana Pâslaru, Speranţa Iacob,Cristian Gheorghe, Irinel Popescu, Dana Tomescu, Liliana Simona Gheorghe
ORIGINAL PAPER, Apr 2018
Article DOI: 10.21614/sgo-23-2-121
Introduction: Acute kidney injury (AKI) following liver transplantation (LT) is a frequent complication and is associated with increased morbidity and mortality.

Aim: To investigate whether the levels of urinary KIM-1 and serum Cystatin C are able to predict early occurrence (within the first 48 hours) of the post-LT renal dysfunction. Methods: The study was conducted on 25 recipients transplanted in the Fundeni Clinical Institute between May 2016 and February 2017. Serum Cystatin C, urinary KIM-1 and serum creatinine were analysed before LT, as well as 4 and 24 hours after graft reperfusion. In defining renal failure, the criteria of The Acute Kidney Injury Network (AKIN) from 2017 were used. All patients received the same renal sparing regimen of immunosuppression (basiliximab, mycophenolate mofetil and delayed tacrolimus).

Results: Ten patients (40%) had early post-LT (<48h) renal dysfunction according to the AKIN classification. In the AKI group, there was a considerable increase of serum Cystatin C at 4 and 24 h after LT in comparison with baseline values (p=0.011), whereas in the group without AKI, the values of Cystatin C dropped (p=0.11). There were no significant differences between the KIM-1 values between the two groups. The single independent risk factor for early post-LT AKI occurrence was serum Cystatin C value 4 hours after hepatic reperfusion. The clinical utility of serum Cystatin C and urinary KIM-1 4 h after reperfusion, evaluated by AUROC, was good (0.79). However, the combination of the two biomarkers and the MELD plus score had a better performance, with an AUROC of 0.83, an 80% sensitivity and 80% specificity for distinguishing patients with early post-transplant AKI from those without AKI.

Conclusion: Early renal dysfunction following LT is frequent (40%) despite using a renal sparing immunosuppression regimen. Combination of serum Cystatin C and urinary KIM-1, 4 hours after hepatic reperfusion and pre-LT MELD-plus score performed the best in screening the early post-LT renal dysfunction.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 4366

Cited by 2 articles

Journal: Medicine, Health Care and Philosophy (1386-7423)
Article: Toward an accelerated adoption of data-driven findings in medicine
Crossref DOI: 10.1007/s11019-018-9845-y
Journal: European Journal of Gastroenterology & Hepatology (0954-691X)
Article: MELD-plus
Crossref DOI: 10.1097/MEG.0000000000001563

Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.